Wangu Zoon, Hsu Katherine K
a Ratelle STD/HIV Prevention Training Center , Massachusetts Department of Public Health , Jamaica Plain , Massachusetts.
b Division of Pediatric Infectious Diseases & Immunology, UMass Memorial Children's Medical Center , Worcester , Massachusetts.
Hum Vaccin Immunother. 2016 Jun 2;12(6):1357-62. doi: 10.1080/21645515.2016.1172754. Epub 2016 May 23.
Human papillomavirus (HPV), the most common sexually transmitted infection in the US and worldwide, can cause cancers, anogenital warts (AGW), and recurrent respiratory papillomatosis (RRP) in men, women, and children. Global incidence of AGW ranges from 160-289 cases per 100,000 person-years and peaks in young men and women in the third decade of life. RRP has an estimated incidence of 3 per 1 million person-years in children. Pre-licensure trial efficacy, modeling and time-trend ecological studies have shown a significant short-term impact of 4vHPV vaccine. In girls aged 15-19 years, a previously published meta-analysis indicated that genital warts decreased significantly by 31%; stratified analysis revealed more substantial reductions in populations with high (≥50 %) vs. low (<50 % ) vaccination coverage (61% vs. 14%). Longer-term monitoring will reveal whether this impact continues under 9vHPV programs, and whether current declines in AGW are mirrored by declines in RRP.
人乳头瘤病毒（HPV）是美国及全球最常见的性传播感染病毒，可在男性、女性和儿童中引发癌症、肛门生殖器疣（AGW）以及复发性呼吸道乳头瘤病（RRP）。全球AGW的发病率为每10万人年160 - 289例，在30岁左右的年轻男性和女性中达到峰值。RRP在儿童中的估计发病率为每100万人年3例。上市前试验疗效、模型分析以及时间趋势生态学研究均显示4vHPV疫苗具有显著的短期影响。在15 - 19岁的女孩中，先前发表的一项荟萃分析表明，生殖器疣显著减少了31%；分层分析显示，疫苗接种覆盖率高（≥50%）的人群与低（<50%）的人群相比，减少幅度更大（分别为61%和14%）。长期监测将揭示这种影响在9vHPV项目下是否持续，以及当前AGW的下降是否会反映在RRP的下降上。
